arrow
A

Antje Blank

Ruprecht Karls University Heidelberg
H指数:26
被引数:2,921

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

How to Optimize Healthy Volunteer Screening and Enrolment in Clinical Trials: A Qualitative and Quantitative Approach to Evaluate Processes and Healthy Volunteers' Perceptions

如何优化临床试验中健康志愿者的筛查与入组:评估流程和健康志愿者感知的定性与定量方法

2026-09-090
OAAI
Interpretation of Pharmacometabolomics Results: Fingerprint of Drug Exposure or Confounder Effects? Insights from a Urinary Metabolomics Study with Voriconazole in Healthy Participants

药代代谢组学结果解释:是药物暴露指纹还是混淆效应?——来自伏立康唑健康受试者尿液代谢组学研究的心得

2026-05-160
OA
144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trial

144周布罗维特德单药治疗慢性丁型肝炎:一项III期随机试验的最终和治疗后结果

2026-04-090
PRE
Effect of the frequently used antiepileptic drugs carbamazepine, gabapentin, and pregabalin on the pharmacokinetics of edoxaban and other oral factor xa inhibitors in healthy volunteers

频繁使用的抗癫痫药物卡马西平、加巴喷丁和普瑞巴林对依度沙班及其他口服Xa因子抑制药在健康志愿者中的药代动力学影响

2025-04-110
OA
Efficacy and safety of BLV monotherapy for chronic hepatitis delta: posttreatment results through 48 weeks after the end of treatment from an interim analysis of a randomised Phase 3 study MYR301
2025-02-010
PRE
Bulevirtide monotherapy in patients with chronic HDV : Efficacy and safety results through week 96 from a phase III randomized trial
2024-10-015
OAAI
Efficacy and Safety of Bulevirtide Monotherapy for Chronic Hepatitis Delta in Patients With and Without Cirrhosis: Results From the Week 96 Interim Analysis of a Phase 3 Randomized Study
2024-10-010
PRE
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D
2023-07-0680
OA